Susan M Lehman

Dr. Susan M Lehman

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2023 in Archives of Virology
Verified
Journal Article
Open access
PDF file
University EnglandUniversity England
University England
ASAndrey N Shkoporov
Andrey N Shkoporov
CLCédric Lood
Cédric Lood
AKAndrew Kropinski
Andrew Kropinski
BDBas E. Dutilh
Bas E. Dutilh
EAEvelien Adriaenssens
Evelien Adriaenssens
This article summarises the activities of the Bacterial Viruses Subcommittee of the International Committee on Taxonomy of Viruses for the period of March 2021−March 2022. We provide an overview of the new taxa proposed in 2021, approved by the Executive Committee, and ratified by vote in 2022. Significant changes to the taxonomy of bacterial viruses were introduced: the paraphyletic morphological families Podoviridae, Siphoviridae, and Myoviridae as well as the order Caudovirales were abolished, and a binomial system of nomenclature for species was established. In addition, one order, 22 families, 30 subfamilies, 321 genera, and 862 species were newly created, promoted, or moved.

3 October 2024 in Microbiology Spectrum
Verified
Journal Article
Closed access
ACAshlan Kunz Coyne
Ashlan Kunz Coyne
MEMirna Eshaya
Mirna Eshaya
CBCallan Bleick
Callan Bleick
SVSamantha Vader
Samantha Vader
BBBiswajit Biswas
Biswajit Biswas
MRMichael J. Rybak
Michael J. Rybak
In the era of antimicrobial resistance, phage-antibiotic combinations offer a promising therapeutic option, yet research on their synergy and antagonism is limited. This study aims to assess these interactions, focusing on protein synthesis inhibitors and cell envelope-active agents against multidrug-resistant bacterial strains. We evaluated synergistic and antagonistic interactions in multidrug-resistant Staphylococcus aureus , Enterococcus faecium , and Pseudomonas aeruginosa strains. Phages were combined with protein synthesis inhibitors [linezolid (LZD), minocycline (MIN), gentamicin (GEN), and azithromycin (AZM)] or cell envelope-active agents [daptomycin (DAP), ceftaroline (CPT), and cefepime (FEP)]. Modified checkerboard minimum inhibitory concentration assays and 24-h time-kill analyses were conducted, alongside one-step growth curves to analyze phage growth kinetics. Statistical comparisons used one-way analysis of variance (ANOVA) and the Tukey test ( P < 0.05). In the checkerboard and 24-h time-kill analyses (TKA) of S. aureus and E. faecium , phage-LZD and phage-MIN combinations were antagonistic (FIC > 4) while phage-DAP and phage-CPT were synergistic (FIC 0.5) (ANOVA range of mean differences 0.52–2.59 log 10 CFU/mL; P < 0.001). For P. aeruginosa , phage-AZM was antagonistic (FIC > 4), phage-GEN was additive (FIC = 1), and phage-FEP was synergistic (ANOVA range of mean differences 1.04–1.95 log 10 CFU/mL; P < 0.001). Phage growth kinetics were altered in the presence of LZD and MIN against S. aureus and in the presence of LZD against a single E. faecium strain (HOU503). Our findings indicate that select protein synthesis inhibitors may induce phage-antibiotic antagonism. However, this antagonism may not solely stem from changes in phage growth kinetics, warranting further investigation into the complex interplay among strains, phage attributes, and antibiotic mechanisms affecting bacterial inhibition. IMPORTANCE: In the face of escalating antimicrobial resistance, combining phages with antibiotics offers a promising avenue for treating infections unresponsive to traditional antibiotics. However, while studies have explored synergistic interactions, less attention has been given to potential antagonism and its impact on phage growth kinetics. This research evaluates the interplay between phages and antibiotics, revealing both synergistic and antagonistic patterns across various bacterial strains and shedding light on the complex dynamics that influence treatment efficacy. Understanding these interactions is crucial for optimizing combination therapies and advancing phage therapy as a viable solution for combating antimicrobial resistance.

21 August 2021 in Archives of Virology
Verified
Journal Article
Open access
PDF file
MKMart Krupovic
Mart Krupovic
University EnglandUniversity England
University England
VMVera V Morozova
Vera V Morozova
MDMike Dyall-Smith
Mike Dyall-Smith
Hanna OksanenHanna Oksanen
Hanna Oksanen
EAEvelien Adriaenssens
Evelien Adriaenssens
In this article, we – the Bacterial Viruses Subcommittee and the Archaeal Viruses Subcommittee of the International Committee on Taxonomy of Viruses (ICTV) – summarise the results of our activities for the period March 2020 – March 2021. We report the division of the former Bacterial and Archaeal Viruses Subcommittee in two separate Subcommittees, welcome new members, a new Subcommittee Chair and Vice Chair, and give an overview of the new taxa that were proposed in 2020, approved by the Executive Committee and ratified by vote in 2021. In particular, a new realm, three orders, 15 families, 31 subfamilies, 734 genera and 1845 species were newly created or redefined (moved/promoted).

9 December 2023
Verified
Book Chapter
Closed access
PDF file
University EnglandUniversity England
University England
EAEvelien Adriaenssens
Evelien Adriaenssens
SLSusan M Lehman
Susan M Lehman
CMCristina Moraru
Cristina Moraru
AKAndrew M. Kropinski
Andrew M. Kropinski

15 November 2023 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
AGAmer El Ghali
Amer El Ghali
KSKyle Stamper
Kyle Stamper
ACAshlan Kunz Coyne
Ashlan Kunz Coyne
DHDana Holger
Dana Holger
RKRazieh Kebriaei
Razieh Kebriaei
MRMichael J. Rybak
Michael J. Rybak
Pseudomonas aeruginosa -associated infective endocarditis represents difficult-to-treat, deep-seated infections. Phage-antibiotic combinations have shown to eradicate multi-drug resistant (MDR) P. aeruginosa , limit the development of phage resistance, and restore antibiotic sensitivity. The objective of this study was to evaluate the activity of phage-ciprofloxacin (CIP) combinations in 4-day ex vivo simulated endocardial vegetation (SEV) models against drug-resistant P. aeruginosa isolates. Two P. aeruginosa isolates, extensively drug-resistant AR351 and MDR I0003-1, were selected for their drug resistance and sensitivity to phage. Three phages [LL-5504721-AH (LL), E2005-C (EC), and 109] and CIP were evaluated alone and in combination for their activity and influence on drug and phage resistance using 24-h time-kill analysis. The three-phage cocktail (q24h) in combination with CIP (400 mg q12h) was then tested in dynamic 4-day ex vivo SEV models, with reduction of log 10 CFU/mL compared using ANOVA with Bonferroni analysis. Compared to other combinations, CIP-LL-EC-109 demonstrated synergistic and bactericidal activity from starting CFU/g against AR351 and I0003-1 (−Δ5.65 and 6.60 log 10 CFU/g, respectively; P < 0.001). Additionally, CIP-LL-EC-109 mitigated phage resistance, while all other therapies had a high degree of resistance to >1 phages, and all phage-containing regimens prevented CIP mean inhibitory concentration increases compared to CIP alone for both AR351 and I0003-1 at 96 h.

9 April 2014
Verified
Book Chapter
Closed access
ASAntonet M. Svircev
Antonet M. Svircev
ACAlan J. Castle
Alan J. Castle
SLSusan M Lehman
Susan M Lehman